Sign in
Not yet taking people in SpainPhase 1/2

Tests HER2-targeted CAR-T cells in adults with advanced HER2-positive breast cancer

Tests ARI-HER2 CAR-T cells in adults with advanced HER2-positive breast cancer.

Key facts

Who runs it
Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer
Where
Barcelona, Madrid, and Pamplona, SpainSee the 3 sites
Registry title
A Phase I First-in-Human Dose Escalation Trial to Evaluate the Safety and Efficacy of ARI-HER2 (HER2BBz CAR-T Cells) in Patients with HER2Positive Advanced Breast Cancer
Status
Not yet recruiting
Phase
Phase 1/2
People taking part
18 people, planned
Started
1 Sept 2026
Expected to end
1 Sept 2030
Type of study
Interventional
Record updated
19 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with advanced breast cancer that is HER2-positive. It tests ARI-HER2 (HER2BBz CAR-T cells) as a first-in-human treatment.

Age
18 to 64 years
Sex
All sexes can join.
Disease stage
Advanced breast cancer that is HER2-positive.
Biomarker or test result
HER2-positive

Main reasons for not taking part

  • Healthy volunteers cannot join.

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 64 years old?

Where in Spain

  • Hospital Clinic de BarcelonaBarcelona, SpainNot yet recruiting
  • Hospital Universitario 12 de OctubreMadrid, SpainNot yet recruiting
  • Clínica Universidad de navarraPamplona, SpainNot yet recruiting

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Plain-language title
Tests HER2-targeted CAR-T cells in adults with advanced HER2-positive breast cancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Fit questions
Built from 2026-527365-30-00, who can take part
Record updated
19 October 2026